Chemotherapy induced nausea and vomiting--prevention and treatment.

Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, and School of Medicine and Pharmacology, University of Western Australia, Australia.
Australian family physician (Impact Factor: 0.67). 10/2007; 36(9):702-6.
Source: PubMed

ABSTRACT Chemotherapy induced nausea and vomiting are among the most feared consequences of cancer treatment. Recent developments in drug treatment make the goal of no nausea or vomiting during chemotherapy realistic.
In this article we review the pathogenesis and management of chemotherapy induced nausea and vomiting.
Regimens to prevent chemotherapy induced nausea and vomiting are guided by the emetogenic potential of the chemotherapeutic agents used. Combined prophylactic therapy targets different pathways, improving the efficacy of prevention and treatment of chemotherapy induced nausea and vomiting. General practitioners have an important role in patients undergoing chemotherapy by reinforcing the importance of prophylactic treatment and administering rescue treatment for patients with breakthrough or prolonged nausea and vomiting postchemotherapy.

  • [Show abstract] [Hide abstract]
    ABSTRACT: PURPOSE: This experimental study was planned to assess the efficiency of the acupressure in prevention of the chemotherapy-induced nausea and vomiting (CINV). METHODS: This single-blinded randomized trial was performed at Istanbul University Institute of Oncology between October 2010 and January 2011. The patients, diagnosed with breast, gynecological, or lung cancer treated by doxorubicin-based- or cisplatin-based treatment were included in the study. Taking the consent of the patients, they were divided into experimental (n = 67) and control groups (n = 53) in line with the randomization list prepared before. The patient description form, Rhodes Index of Nausea, Vomiting, and Retching (INVR), and Functional Assessment of Cancer Therapy-General were used in data collection. Non-parametric tests were applied. RESULTS: The patients in the experimental and control groups were identical in terms of sociodemographic features and their conditions. Most of the patients were married (84 %), and some were primary school graduates (41.7 %) and had mid-level income (54.2 %). In nausea-vomiting-retching, experiences of the patients before using a placebo and a real acupressure were identical and similar changes had been observed during 5 days after the treatment. It has been determined that there was no difference between the groups statistically. A similar result has been observed when the impact of acupressure on the subgroups of sociodemographic features and condition were examined, and it has been concluded that real acupressure application cannot increase the quality of life. CONCLUSION: It has been determined that CINV is directly related to the treatment, and acupressure wristband was not an effective approach in preventing CINV.
    Supportive Care in Cancer 06/2012; · 2.09 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Physicians frequently prescribe 'stat' orders that need to be actioned immediately or within a limited time frame. This process can be time consuming and expensive. Stat medications are reserved for the highest priority orders and life-threatening situations that need to be dealt with immediately or within a limited time frame. The goals of this study were to evaluate whether stat medications in a teaching hospital were ordered appropriately and to assess the rationale for the stat order. The study was carried out between July and August 2009 in Masih Daneshvari Hospital. All newly admitted patients' charts were reviewed and the records of all inpatients who received at least one stat order were included in the study. Detailed analyses were undertaken to examine the stat use of agents and the rationale for their prescription. Several different guidelines were used to evaluate the rationale for the prescriptions. Charts for 175 patients were reviewed. Of these, 109 (62.3%) patients received a total of 220 stat orders. The mean number of stat orders on each chart of patients who received stat orders was 2.0. Stat orders were divided into two categories: 146 (66.4%) that were administered only once and 74 (33.6%) that were reordered. The internal medicine ward accounted for the most stat medications (35%). The major reasons for stat medication orders were: prophylaxis or management of emesis (22.3%), control of dyspnoea (15.9%), preoperative medications (8.2%) and treatment of exacerbations of chronic obstructive pulmonary disease (7.2%). Hydrocortisone (14.1%), dexamethasone (11.3%), granisetron (9.5%), ceftriaxone (8.6%) and morphine (6.8%) accounted for the most common stat orders. Analysis showed that 133 of the total 220 stat orders (60.5%) were prescribed appropriately; the rationale for 19 orders (8.6%) could not be evaluated. This study showed that most stat orders at Masih Daneshvari Hospital during the study period were prescribed appropriately. Further investigations are recommended to evaluate the outcomes of unnecessary stat orders with respect to adverse drug events.
    Clinical Drug Investigation 01/2011; 31(4):231-5. · 1.70 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Gene directed enzyme prodrug therapy (GDEPT) of cancer aims to improve the selectivity of chemotherapy by gene transfer, thus enabling target cells to convert nontoxic prodrugs to cytotoxic drugs. A zone of cell kill around gene-modified cells due to transfer of toxic metabolites, known as the bystander effect, leads to tumour regression. Here we discuss the implications of either striving for a strong bystander effect to overcome poor gene transfer, or avoiding the bystander effect to reduce potential systemic effects, with the aid of three successful GDEPT systems. This review concentrates on bystander effects and drug development with regard to these enzyme prodrug combinations, namely herpes simplex virus thymidine kinase (HSV-TK) with ganciclovir (GCV), cytosine deaminase (CD) from bacteria or yeast with 5-fluorocytodine (5-FC), and bacterial nitroreductase (NfsB) with 5-(azaridin-1-yl)-2,4-dinitrobenzamide (CB1954), and their respective derivatives.
    Molecules 11/2009; 14(11):4517-45. · 2.10 Impact Factor